President Cyril Ramaphosa launched a national rollout of lenacapavir, a twice-yearly injectable HIV prevention drug, in Secunda, Mpumalanga, on June 5, 2026 [1].
The rollout aims to curb new HIV infections in a nation that carries the world's highest HIV burden [2]. By moving away from daily oral PrEP pills, the government hopes to overcome adherence limitations and reach more at-risk populations [2].
Lenacapavir requires administration only twice per year [3]. This frequency represents a significant shift in prevention strategy, reducing the burden on patients who previously relied on daily medication to avoid infection [3].
Thousands of South Africans previously signed up for clinical trials to test the efficacy of the drug [4]. The government's push for widespread access follows these trials, which highlighted the potential for long-acting preventatives to stabilize public health outcomes [4].
During the launch events, the impact of the drug was illustrated through individual stories, including a 19-year-old participant [4]. The health ministry said the injection is intended to bridge the gap for those who cannot maintain a strict daily pill regimen due to social stigma, or logistical barriers [2].
Despite the launch, officials said the rollout continues amid limited supplies [1]. The government is working to scale the distribution to ensure that the injection reaches the most vulnerable regions of the country [1].
“South Africa carries the world's highest HIV burden.”
The transition from daily oral PrEP to a twice-yearly injection could drastically increase adherence rates in high-risk populations. By removing the need for daily pill consumption, South Africa reduces the risk of 'pill fatigue' and the social stigma associated with visible medication, potentially slowing the rate of new infections in the most affected region globally.
